Form 10-Q Arcutis Biotherapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho
May 15, 2024 5:18 AM EDTMizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $18.00 (from $17.00) while maintaining a Buy rating.
The analyst comments "1Q24 was strong, with Zoryve (Cream + Foam) beating our above-Consensus forecasts driven by significantly better-than-expected gross-to-nets (GtN),... More
